Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 1998Blood Coagulation & Fibrinolysis

Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery

View Full Paper
Ask AI
Bookmark
Share

Key result

Reviparin and enoxaparin demonstrated equivalent efficacy for the prevention of venographically confirmed DVT after total hip replacement (12% vs 10%, respectively).

Why the study?

Does reviparin prevent venographically confirmed DVT as effectively as enoxaparin in patients undergoing total hip replacement?

Population

498 patients undergoing elective total hip replacement

Comparison

Reviparin 4200 IU anti-Xa given preoperatively vs Enoxaparin 40 mg given preoperatively

Design

RCT, Randomly assigned, Double-blind, double-dummy

Authors

ASA. Plan sNVN VochelleCentre Hospitalier de La RochelleMFM FagolaCentre Hospitalier de La Rochelle

Discussion

Loading...

Member takes

Overview

Supports interchangeable use of either agent for DVT prophylaxis after total hip replacement; confirms LMWH equivalence in RCT evidence.

Study Design

Type

RCT (n=498)

Blinding

Double-blind, double-dummy

Randomization

randomly assigned

Structured PICO

Does reviparin prevent venographically confirmed DVT as effectively as enoxaparin in patients undergoing total hip replacement?

P
Population
498 patients undergoing total hip replacement evaluated for the prevention of postoperative venous thromboembolism.
I
Intervention
Reviparin 4200 IU anti-Xa given preoperatively
C
Comparator
Enoxaparin 40 mg (approximately 4000 IU anti-Xa) given preoperatively
O
Outcome
Venographically confirmed deep vein thrombosis (DVT)hard clinical

Main Result

Absolute Event Rate: 12% vs 10%

Reviparin and enoxaparin demonstrate equivalent efficacy and safety for the prevention of deep vein thrombosis after elective total hip replacement.

Cite This Study

s et al. (1998) conducted an RCT in Total hip replacement (n=498). Reviparin vs. Enoxaparin (40mg) was evaluated on Venographically confirmed deep vein thrombosis (DVT). Reviparin and enoxaparin demonstrated equivalent efficacy for the prevention of venographically confirmed DVT after total hip replacement (12% vs 10%, respectively).

synapsesocial.com/papers/6a97d1b7e6df4f2d12366754https://doi.org/10.1097/00001721-199809000-00007
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.1994 · 221 citations
  2. 2Prevention of Postoperative Venous Thrombosis: A Randomized Trial Comparing Unfractionated Heparin with Low Molecular Weight Heparin in Patients Undergoing Total Hip Replacement1988 · 257 citations
  3. 3Low-Molecular-Weight Heparin (Enoxaparin) as Prophylaxis against Venous Thromboembolism after Total Hip Replacement1996 · 462 citations
  4. 4An Equivalence Study of Two Low-Molecular-Weight Heparins in the Prevention and Treatment of Deep-Vein Thrombosis after Total Hip Replacement2000 · 13 citations
  5. 5Prevention of Deep Vein Thrombosis after Hip Replacement1999 · 92 citations